---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-083928"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2024-07-16T23:59:59+00:00"
generated_at: "2026-05-31T20:33:44.902392+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Genentech terminates migoprotafib collaboration; Relay loses future milestones

## Summary
- Genentech terminated without cause; effective 180 days after July 11, 2024.
- Relay had received $121.8M total ($75M upfront + $45M milestones + R&D costs).
- No further milestone or royalty payments due after termination date.
- Relay regains full rights to migoprotafib (SHP2 inhibitor) and all associated data.
- Termination removes expected future payments; drug development status uncertain.

## SEC filing metadata
- accession: 0000950170-24-083928
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2024-07-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017024083928/0000950170-24-083928-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017024083928/rlay-20240711.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-083928
- JSON: https://secwatch.observer/filing/0000950170-24-083928.json
- Plain text: https://secwatch.observer/filing/0000950170-24-083928.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.